Fortress Biotech, INC. (FBIOP) — 8-K Filings

8-K Filings (23)

• Fortress Biotech Files 8-K — Dec 15, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on December 15, 2025, reporting on other events and financial statements. The filing details the company's incorporation in
• 8-K Filing — Nov 17, 2025
• Fortress Biotech Files 8-K on Oct 1, 2025 — Oct 1, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharma
• Fortress Biotech Files 8-K with Office and Name Change Info — Jul 16, 2025 Risk: low
  On July 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1111 Kane Concourse,
• Fortress Biotech Reports on Shareholder Vote — Jun 23, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The filing pertains to thei
• Fortress Biotech Completes Asset Acquisition/Disposition — Jun 5, 2025 Risk: medium
  Fortress Biotech, Inc. filed an 8-K on May 30, 2025, reporting the completion of an acquisition or disposition of assets. The filing also includes financial sta
• Fortress Biotech Announces Executive and Director Changes — Apr 16, 2025 Risk: medium
  Fortress Biotech, Inc. announced on April 15, 2025, changes in its board of directors and executive officers. The company also disclosed information regarding c
• Fortress Biotech Enters Material Definitive Agreement — Mar 10, 2025 Risk: medium
  On March 9, 2025, Fortress Biotech, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive office
• Fortress Biotech Relocates HQ, Confirms Fiscal Year End — Jan 16, 2025 Risk: low
  On January 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1111 Kane Concour
• Fortress Biotech Files 8-K — Jan 6, 2025 Risk: medium
  Fortress Biotech, Inc. filed an 8-K on January 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts
• Fortress Biotech Files 8-K — Dec 16, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on December 13, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amoun
• Fortress Biotech Files 8-K Report — Nov 4, 2024 Risk: low
  On November 4, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing indicates that the company is incorporated in Delaware and its principal executive o
• Fortress Biotech Enters Material Agreement, Reports Equity Sales — Sep 23, 2024 Risk: medium
  Fortress Biotech, Inc. announced on September 19, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Fortress Biotech Files 8-K on Agreements and Equity Sales — Jul 25, 2024 Risk: medium
  On July 25, 2024, Fortress Biotech, Inc. filed an 8-K detailing several significant events. These include entering into and terminating material definitive agre
• Fortress Biotech Enters Material Definitive Agreement — Jul 19, 2024 Risk: medium
  On July 15, 2024, Fortress Biotech, Inc. entered into a material definitive agreement. The filing does not provide specific details on the nature of the agreeme
• Fortress Biotech Files 8-K — Jul 5, 2024 Risk: low
  On July 5, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific n
• Fortress Biotech Files 8-K on Equity Sale — Jun 28, 2024 Risk: medium
  On June 27, 2024, Fortress Biotech, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The company, incorporated in Delaware, issued
• Fortress Biotech Files 8-K for Corporate Changes — Jun 25, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on June 25, 2024, reporting a change in its corporate structure or bylaws as of June 19, 2024. The filing also includes fina
• Fortress Biotech Sells Fortress Vision for $15M — May 29, 2024 Risk: medium
  Fortress Biotech, Inc. announced on May 23, 2024, a definitive agreement to sell its subsidiary, Fortress Vision, to NovaSight Ltd. for $15 million in cash. The
• Fortress Biotech Files 8-K on Financials — May 15, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• Fortress Biotech Files 8-K on Financials — Mar 28, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Fortress Biotech 8-K: Officer/Director Changes & Comp Arrangements — Jan 26, 2024
  Fortress Biotech, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 25, 2024, related to the departure or election of directors
• Fortress Biotech Enters Material Definitive Agreement — Jan 3, 2024
  Fortress Biotech, Inc. filed an 8-K on January 3, 2024, reporting an event on December 29, 2023, related to an entry into a material definitive agreement. The f

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX